[New] Drug pricing policy changes in the U.S. are expected to reduce prices under Medicare / Medicaid and in commercial markets but will likely have minimal impact on prices in international markets.
https://www.lazard.com
[New] U.S. Administration's Drug Pricing Policy Expected to Decrease Medicare / Medicaid and Commercial Drug Prices, Have Limited or No Impact on European Drug Prices, and Result in Fewer Biopharmaceutical Companies Launching Drugs Outside the U.S.
https://www.lazard.com
[New] The next transformative phase of weight-loss medication is upon us, with the US Food and Drug Administration approving Novo Nordisk's highly anticipated oral GLP-1 drug - with a starting dose available in early January for US$149.
New Atlas
[New] 2025 will bring AI innovations across pharmaceutical drug discovery, genetics, and biotech.
AI Health Uncut
[New] Danish pharmaceutical giant Novo Nordisk has announced its Wegovy pill has been approved for commercial sale by the US Food and Drug Administration and will arrive on shelves early in January.
Just Food
[New] The Trump administration announces an agreement with Pfizer and unveils a major drug pricing plan in which the pharma giant will sell its drugs at lower prices based on MFN pricing. / USA
MM+M - Medical Marketing and Media
[New] The US Food and Drug Administration has approved the Wegovy pill (once-daily oral semaglutide 25 mg) to reduce excess body weight and maintain weight reduction long term and to reduce the risk of major adverse cardiovascular events.
Novo Nordisk
[New] Improved policy clarity following most large drugmakers' drug pricing agreements with the Trump administration reduced a key source of uncertainty, while a rebound in mergers and acquisitions helped revive investor appetite for risk across the biotech industry.
Yahoo Finance
[New] On the government level, the Trump Administration's new approach to most-favored-nation (MFN) drug pricing, through things like direct-to-consumer (DTC) medication platforms expected to launch in 2026, is set to further shake up the pharmacy industry.
Drug Topics
[New] Most Favored Nation Agreements: The White House has entered agreements with pharmaceutical companies to align U.S. drug prices with international standards by 2026, offering discounts and temporary tariff relief in exchange for expanded domestic manufacturing commitments.
www.carelonrx.com
[New] Medicare price negotiations on biologics with imminent biosimilars could lead to near-term savings, but greater savings are likely from biosimilar competition.
Managed Healthcare Executive
Looking ahead to 2026, PhaseV plans to deepen its work with global sponsors and expand its vertical AI platform to further accelerate drug pipelines, optimize study design and site selection, and improve patient outcomes across diverse therapeutic areas.
Cision PR Newswire
The 2025 Nobel Prize in medicine honored advances in regulatory T cell (Treg) therapy, and the first Treg-based therapy could be approved by the U.S. Food and Drug Administration for blood cancers as early as in 2025.
Scientific American
ACO LEAD will include incentives for Medicare beneficiaries to participate, including through cost-sharing for outpatient services and, by 2029, the option to buy down their Medicare prescription drug premiums.
Healthcare Dive
The regulatory filing in the EU seeks approval for a 7.2 mg dose of the drug, which Novo Nordisk claims provides an option for greater weight loss potential than what is currently being offered by the available doses (0.25 mg, 0.5 mg, 1 mg, 1.7 mg and 2.4 mg).
Yahoo Finance
Novo's patents on semaglutide are set to start expiring in 2026, and biosimilar producers are gearing up to compete, which will inevitably lead to a drop in prices.
Chemistry World
The Trump administration will direct the Food and Drug Administration to send warning letters to 12 manufacturers and retailers they say are conducting illegal marketing of breast binders to children.
Healthcare Dive
Forthcoming guidance from the U.S. Food and Drug Administration will shape the compliance landscape quickly.
JD Supra
The first cohort of 10 negotiated drug prices will take effect in 2026, projected to save beneficiaries $1.5 billion in annual out-of-pocket expenses, setting a precedent for expanded affordability across Part D plans.
Total RX
The U.K. government's drug rebate tax will fall to 14.5% for new drugs in 2026 - down from nearly 23%.
MM+M - Medical Marketing and Media
Last updated: 30 December 2025
Hi,
Would you like a quick online demo of our service from an experienced member of our team?
